Abstract
Neuroendocrine tumors (NET) are relatively rare tumors characterized by their ability to produce and release different peptide hormones and bioctive amines, the effect of which influenced the clinical picture of the disease. Functional imaging with different radiopharmaceuticals (in the Czech republic available I-123/I-131 MIBG, In-111 or Tc-99m labeled analogs of somatostatin and F-18 FDG) is used besides conventional imaging methods i their diagnosis.
Radionuclide therapy with unsealed sources in indicated in patients with NET resistent to systemic therapy.